Cardiff Oncology, Inc. (CRDF)

Market Cap	79.97M
Revenue (ttm)	391,000
Net Income (ttm)	-39.47M
Shares Out	44.68M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,340
Open	1.78
Previous Close	1.79
Day's Range	1.76 - 1.79
52-Week Range	1.13 - 3.56
Beta	1.60
Analysts	Buy
Price Target	8.16 (+363.64%)
Earnings Date	Feb 23, 2023

About CRDF

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for met...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: CRDF

Financial Performance

In 2021, CRDF's revenue was $359,000, a decrease of -1.91% compared to the previous year's $366,000. Losses were -$28.32 million, 25.3% more than in 2020.

Analyst Forecast

According to 11 analysts, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is $8.16, which is an increase of 363.64% from the latest price.

Price Target

$8.16

(363.64% upside)

Analyst Consensus: Buy